[Pharmacological characteristics and clinical study results of the first RAS inhibitor sotorasib (LUMAKRAS®) for non-small cell lung cancer with KRAS G12C mutation].

Abstract excerpt

Sotorasib (LUMAKRAS®) is the first RAS inhibitor that selectively binds to KRAS G12C and irreversibly inhibits the conformational change from the inactive to active form of KRAS. The gene mutation that produces KRAS G12C protein, which is the target of sotorasib, is one of the oncogenic drivers observed in non-small cell lung cancer (NSCLC), and the KRAS G12C mutation causes conformational changes to maintain...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antineoplastic Agents
• Share to Carcinoma, Non-Small-Cell Lung